Medicus, Vol. 31 No. 2 Osteoporoza, 2022.
Pregledni rad
Pharmacological Treatment of Osteoporosis: An Update
Ines Bilić-Čurčić
Silvija Canecki Varžić
Ema Schönberger
Sažetak
Osteoporosis (OP) is a chronic bone disease characterized by disturbed bone microarchitecture, which leads to reduced bone mass and increased risk of fractures. Antiresorptive drugs, especially bisphosphonates, are currently the first choice in the treatment of osteoporosis in most countries. However, their limitations prompted the development of osteoanabolic drugs such as teriparatide and romosozumab, with their own adverse effects. Still, it is undeniable that the benefits of antiosteoporosis drugs outweigh the potential risks. In patients at high or very high fracture risk, sequential or combination therapies with an anabolic agent as an initial agent may be considered. Due to the growing prevalence of osteoporosis, great efforts are being made to develop next-generation drugs with maximum effectiveness and an acceptable safety profile. Achieving this goal requires a better insight in different signaling pathways involved in the pathogenesis of osteoporosis. The greatest efforts have been made in the development of drugs that affect the modification of the Wnt signaling pathway, which can have anti-resorptive and/or osteoanabolic effects depending on the target signaling molecule.
Ključne riječi
osteoporosis; antiresorptive drugs, anabolic drugs; Wnt signaling pathway; bone formation
Hrčak ID:
291566
URI
Datum izdavanja:
17.1.2023.
Posjeta: 662 *